Chronic Lymphocytic Leukemia (CLL)

What is the key distinction between chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)?

In the context of monoclonal B-cell lymphocytosis (MBL), what distinguishes 'CLL/SLL-type MBL' from 'low-count MBL' according to WHO-HAEM5 criteria?

Considering the differences between CLL, SLL and MBL, which combination of findings would be most indicative of SLL rather than CLL or MBL?

What is the rationale behind performing FISH analysis in CLL patients before initiating therapy, and what specific genetic abnormalities are most critical to identify?

What distinguishes the prognostic implications of mutated versus unmutated IGHV gene status in CLL, and how does this difference manifest in the natural history of the disease?

How do the Rai and Binet staging systems differ in their approach to stratifying CLL patients, and what are the key factors each system considers?

According to current iwCLL guidelines, what criteria must be met to initiate treatment for CLL, especially considering the role of active surveillance?

In determining when to initiate CLL treatment, which of the following scenarios would most likely warrant immediate therapeutic intervention, according to established criteria?

How do BTK inhibitors disrupt CLL cell survival, and what is their significance in first-line therapy, particularly for patients with specific genetic mutations?

What is the rationale for using monoclonal antibodies in CLL treatment, and how do they complement targeted therapies and chemotherapy?

What factors are considered critical when selecting a relapse treatment for CLL, considering the personalization of treatment decisions?

How does a rapid blood lymphocyte doubling time(LDT) impact the prognosis and management of CLL, and what other factors related to cytogenetics influence therapy decisions?

What are the implications of increased LDH levels in CLL, and how might these levels relate to the suspicion of disease transformation, such as Richter's syndrome?

What key characteristics differentiate mutated IGHV CLL from unmutated IGHV CLL with respect to stage, white blood cell count, lymphocyte doubling time, and genetic risks?

A patient with CLL presents with AIHA and ITP. What underlying complication of CLL is likely contributing to their symptoms, and what is the standard treatment approach for this complication?

A patient undergoing CLL treatment develops a drug-related painful lymph node enlargement, fever, rash, and bone pain. Which complication is most likely occurring, and how should it be managed?

What risk factors are associated with Richter’s transformation, and how does the treatment approach differ from standard CLL management?

In the context of using targeted therapies for CLL treatment, how would the presence of a TP53 mutation or a 17p deletion impact the choice of initial therapy?

What are the major advantages and disadvantages of using stem cell transplantation in CLL, particularly regarding patient eligibility and disease characteristics?

A patient with CLL presents with rapidly enlarging lymph nodes, fevers, and unintentional weight loss after being stable for several years on a watch and wait approach. Which complication is the most likely cause?

Which of the following accurately describes the role and timing of bone marrow assessment in the diagnostic evaluation of CLL?

A CLL patient with deletion 17p who has failed fludarabine and bendamustine-based therapies is being considered for targeted therapy. Which agent is most appropriate and directly addresses the adverse risk associated given the prior treatments?

How does ZAP-70 expression correlate with IGHV mutational status in CLL, and what are the subsequent clinical implications of assessing ZAP-70 expression levels?

A CLL patient presents in stage 0 of the Rai classification and asymptomatic. What strategy is more beneficial for the patient?

A CLL patient has a family history of CLL, what are the chances of having the disease?

In a suspected case of CLL, what blood assessment must be done for diagnosis confirmation?

Which of the following is NOT a diagnostic criteria for CLL?

What adverse effects are associated with CLL complications from treatment?

WHICH IS ABSENT IN MBL?

Which genetic abnormality carries a good prognosis?

What percentage of CLL patient develop diffuse large B-cell lymphoma?

What is the epidemiology of CLL?

Which of the following is not an indication for starting CLL therapy?

A CLL patient has a haemoglobin level of <10g/dL. What can be said about his situation?

Men are how much likely to be diagnosed with CLL than woman?